Latest Insider Transactions at Opiant Pharmaceuticals, Inc. (OPNT)
This section provides a real-time view of insider transactions for Opiant Pharmaceuticals, Inc. (OPNT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of OPIANT PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of OPIANT PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Craig A Collard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
55,822
-98.21%
|
$1,116,440
$20.0 P/Share
|
|
Mar 02
2023
|
Gabrielle Alison Silver Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,343
-95.72%
|
$466,860
$20.0 P/Share
|
|
Mar 02
2023
|
Richard J Daly Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,800
-87.18%
|
$156,000
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,916
-88.12%
|
$638,320
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,751
-79.14%
|
$415,020
$20.0 P/Share
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,680
-100.0%
|
$193,600
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
82,006
-83.23%
|
$1,640,120
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,100
-100.0%
|
$102,000
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,720
-100.0%
|
$1,254,400
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
27,450
-100.0%
|
$549,000
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,548
-81.85%
|
$470,960
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Masuoka K. Lorianne Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,000
-75.0%
|
$80,000
$20.0 P/Share
|
|
Mar 02
2023
|
Ann L. Mac Dougall Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,179
-96.45%
|
$563,580
$20.0 P/Share
|
|
Mar 02
2023
|
Thomas T. Thomas Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,375
-91.92%
|
$247,500
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,990
-81.82%
|
$679,800
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
David D O'Toole Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,248
-88.58%
|
$724,960
$20.0 P/Share
|
|
Mar 02
2023
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Jan 27
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
480
-2.18%
|
$9,600
$20.26 P/Share
|
|
Jan 27
2023
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
444
-1.37%
|
$8,880
$20.26 P/Share
|
|
Jan 27
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
610
-3.15%
|
$12,200
$20.26 P/Share
|
|
Jan 27
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,358
-1.77%
|
$27,160
$20.26 P/Share
|
|
Jan 27
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
541
-1.56%
|
$10,820
$20.26 P/Share
|
|
Jan 09
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,183
-1.52%
|
$23,660
$20.2 P/Share
|
|
Jan 09
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
369
-1.65%
|
$7,380
$20.2 P/Share
|
|
Jan 09
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
469
-2.37%
|
$9,380
$20.2 P/Share
|
|
Jan 09
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
415
-1.18%
|
$8,300
$20.2 P/Share
|
|
Jan 05
2023
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
1,313
-3.89%
|
$26,260
$20.2 P/Share
|
|
Jan 05
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,600
-4.35%
|
$32,000
$20.2 P/Share
|
|
Jan 05
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,806
-8.35%
|
$36,120
$20.2 P/Share
|
|
Jan 05
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,029
-6.07%
|
$100,580
$20.2 P/Share
|
|
Jan 05
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,421
-5.97%
|
$28,420
$20.2 P/Share
|
|
Jul 20
2022
|
Matthew R. Ruth Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,084
-3.5%
|
$10,840
$10.62 P/Share
|
|
Jul 14
2022
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
627
-2.56%
|
$6,897
$11.85 P/Share
|
|
Jul 14
2022
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
779
-2.07%
|
$8,569
$11.1 P/Share
|
|
Jul 14
2022
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
691
-2.01%
|
$7,601
$11.16 P/Share
|
|
Jul 14
2022
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,246
-2.64%
|
$24,706
$11.11 P/Share
|
|
Jun 27
2022
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+6.06%
|
-
|
|
Jun 27
2022
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+5.49%
|
-
|
|
Jun 27
2022
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.56%
|
-
|
|
Jun 27
2022
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+5.05%
|
-
|
|
Jun 27
2022
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+7.26%
|
-
|
|
Jun 27
2022
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.46%
|
-
|
|
Jun 15
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
900
-4.47%
|
$9,000
$10.6 P/Share
|
|
Jun 14
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
7,225
-26.42%
|
$72,250
$10.9 P/Share
|
|
Jun 14
2022
|
Thomas T. Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+13.91%
|
-
|